Search hospitals > Texas > Dallas
UT Southwestern/Simmons Cancer Center-Dallas
Claim this profileDallas, Texas 75390
Global Leader in Parotid Gland Cancer
Global Leader in Cancer
Conducts research for Adult T-Cell Leukemia/Lymphoma
Conducts research for Relapse
Conducts research for Brain Tumor
688 reported clinical trials
69 medical researchers
Summary
UT Southwestern/Simmons Cancer Center-Dallas is a medical facility located in Dallas, Texas. This center is recognized for care of Parotid Gland Cancer, Cancer, Adult T-Cell Leukemia/Lymphoma, Relapse, Brain Tumor and other specialties. UT Southwestern/Simmons Cancer Center-Dallas is involved with conducting 688 clinical trials across 654 conditions. There are 69 research doctors associated with this hospital, such as Martha M. Pacheco, David Miller, MD, Matthew Campbell, MD, and Syed M. Kazmi.Area of expertise
1Parotid Gland Cancer
Global LeaderStage IV
Stage III
Stage II
2Cancer
Global LeaderStage IV
Stage I
Stage II
Top PIs
Martha M. PachecoSaint Luke's Cancer Institute - Boise8 years of reported clinical research
Expert in Cancer
Expert in Brain Tumor
37 reported clinical trials
89 drugs studied
David Miller, MDParkland Memorial Hospital2 years of reported clinical research
Expert in Parotid Gland Cancer
Studies Cervical Adenocarcinoma
21 reported clinical trials
40 drugs studied
Matthew Campbell, MDUT Southwestern/Simmons Cancer Center-Dallas3 years of reported clinical research
Studies Parotid Gland Cancer
Studies Bladder Cancer
19 reported clinical trials
36 drugs studied
Syed M. KazmiUT Southwestern/Simmons Cancer Center-Dallas7 years of reported clinical research
Studies Colorectal Cancer
Studies Colon Cancer
17 reported clinical trials
33 drugs studied
Clinical Trials running at UT Southwestern/Simmons Cancer Center-Dallas
Lung Cancer
Cancer
Parotid Gland Cancer
Kidney Cancer
Prostate Cancer
Colon Cancer
Non-Small Cell Lung Cancer
Bladder Cancer
Colorectal Cancer
Uterine Cancer
Surgery + Chemotherapy
for Pleuropulmonary Blastoma
This phase III trial tests how well surgery plus chemotherapy compared to surgery alone works in treating patients with type I pleuropulmonary blastoma (PPB), and tests how well surgery plus standard chemotherapy with the addition of topotecan works compared to surgery plus standard chemotherapy alone in treating patients with type II and III PPB. Historically, most children with type I PPB had surgery and approximately 40% of children with type I PPB received chemotherapy following their surgery, usually for 22-42 weeks. There has not been a consistent standard for which children with type I PPB receive chemotherapy after surgery. For patients whose tumor has been removed completely with surgery, observation without chemotherapy may work as well as giving chemotherapy after surgery in preventing a return of the PPB tumor. The standard chemotherapy for patients with types II or III PPB in the United States is four cycles of IVADo (ifosfamide, vincristine, dactinomycin, and doxorubicin) followed by 8 cycles of IVA (ifosfamide, vincristine and dactinomycin). Ifosfamide is in a class of medications called alkylating agents. It works by slowing or stopping the growth of tumor cells in the body. Vincristine is in a class of medications called vinca alkaloids. It works by stopping tumor cells from growing and dividing and may kill them. Dactinomycin is a type of antibiotic that is only used in cancer chemotherapy (antineoplastic antibiotic). It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill tumor cells. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's DNA and may kill tumor cells. It also blocks a certain enzyme needed for cell division and DNA repair. Topotecan is in a class of medications called topoisomerase I inhibitors. It works by interfering with tumor cell DNA which kills them. Giving topotecan in addition to standard IVADo and IVA chemotherapy regimens may shrink the cancer as well as or better than the standard therapy or could decrease the chance the tumor spreads while causing fewer side effects.
Recruiting2 awards Phase 38 criteria
Chemotherapy + Immunotherapy vs. Immunotherapy
for Advanced Lung Cancer
This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and chemotherapy may help stabilize lung cancer.
Recruiting2 awards Phase 3
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at UT Southwestern/Simmons Cancer Center-Dallas?
Where is UT Southwestern/Simmons Cancer Center-Dallas located?
Who should I call to ask about financial aid or insurance network?
What insurance does UT Southwestern/Simmons Cancer Center-Dallas accept?
What awards or recognition has UT Southwestern/Simmons Cancer Center-Dallas received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.